Great work today by callmecrazy. NIAID To Try "B"
Post# of 72440
(Total Views: 772)
Posted On: 08/21/2022 2:42:00 PM
Great work today by callmecrazy.
NIAID To Try "B" As Broad- Spectrum Anti-Coronavirus Prophylactic
This is my opinion based on a substantial amount of evidence.
In 2020, George Mason University reported in their testing of Brilacidin:
" Brilacidin’s ability to disrupt viral integrity and block viral entry indicates it has the added potential to prevent infection, upon appropriate formulation, as a prophylactic."
https://investorshub.advfn.com/boards/read_ms...=169609082
"University of Arizona and University of California-San Francisco scientists characterized the antiviral activity of Brilacidin against multiple endemic human coronaviruses (HCoVs), including HCoV-OC43, HCoV-229E, HCoV-NL63, and SARS-CoV-2, in human cell lines...
Mechanistic studies revealed Brilacidin exerts antiviral activity by interfering with viral attachment to host cells by binding to heparan sulfate proteoglycans (HSPGs). HSPGs are important co-receptors through which different viruses gain entry into host cells, thus providing an attractive target for the development of broad-spectrum antivirals. Beyond exhibiting this blocking property, Brilacidin was also shown to target viral proteins directly, acting through a virucidal property. This dual antiviral mechanism of action suggests Brilacidin may be well-suited for prophylactic development and less likely to be subject to drug resistance.
http://www.ipharminc.com/press-release/2022/3...brilacidin
And completing the trifecta:
"Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma (P.1) and Alpha (B.1.1.7) variants of SARS-CoV-2.
Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested..."
http://www.ipharminc.com/press-release/2022/6...esearchers
Even Brilacidin's COVID-19, phase 2, that many considered a failure, provided support for Brilacidin's potential as a broad-based, anti-coronavirus prophylactic.
"If a patient started study treatment within fewer than 7 days of onset of COVID-19 symptoms, patients in the Brilacidin 5-dose group achieved sustained recovery more quickly compared to the pooled placebo group (p=0.03). For this patient population, early treatment with Brilacidin from onset of symptoms appeared to have a potential positive impact on time to sustained recovery (the study’s primary endpoint), suggesting cases that can be treated close to initial onset of disease may be an attractive population to target for Brilacidin treatment"
https://www.ipharminc.com/press-release/2022/...-use-cases
The potential for Brilacidin as a broad-spectrum, anti-coronavirus prophylactic has been demonstrated in three university's testing (in vitro) and one COVID-19 phase 2 study (in vivo).
The "Omicron" variant of COVID-19 is still a pathogen of major concern for NIAID.
"The Omicron was first detected in November 2021 and has become the most dominant strain of COVID-19...The majority of people likely infected with the omicron variant of COVID-19 were unaware, according to a study from a medical center in Los Angeles, Calif...Our study findings add to evidence that undiagnosed infections can increase transmission of the virus."
https://www.npr.org/2022/08/19/1118402942/omi...2-U9YAlny4
And just in case you were thinking there's no more "gold in them-thar COVID hills:
"According to the latest market intelligence research report by InsightAce
Analytic, the global COVID-19 Therapeutics market size was valued at US$ 10.2
Billion in 2021, and it is expected to reach US$ 25.6 Billion in 2030, record
a promising CAGR of 10.7% from 2021 to 2030."
https://www.bloomberg.com/press-releases/2022...e-analytic
Testing at 3 universities (in vitro) and B's COVID P-2 (in vivo), all indicate that B-AV's "blocking" attribute indicate it is well-suited for the role of broad-spectrum, anti-coronavirus prophylactic. B's COVID P-2 went a long way in helping researchers to see that B's role, at least insofar as COVID is concerned, is probably preventing COVID from entering the body and NOT eradicating COVID after it has built-up a strong position in the body.
The data suggest that prophylactic B-COVID will keep the virus/variant out of the body and that COVID may not be able to created a "Trojan Horse" (mutation) to get around it.
I believe NIAID will, ultimately, conduct many clinical trials, researching Brilacidin's antiviral attributes against many viral families, but, given the immediate threat still posed by COVID/Omicron and data suggesting B's ability to inhibit this virus, I think NIAID will conduct this B-COVID prophylactic trial first.
After approval and in short order, I believe B-COVID could become a billion-dollar indication practically overnight, based only on worldwide sales to governments, who will stockpile and distribute.
Message in reply to:
NIAID has a high-degree of interest in Brilacidin and I can't wait to see which direction they move in. Will it be "B" as a COVID prophylactic, broad-spectrum antiviral or possibly something involving monkeypox?
NIAID To Try "B" As Broad- Spectrum Anti-Coronavirus Prophylactic
This is my opinion based on a substantial amount of evidence.
In 2020, George Mason University reported in their testing of Brilacidin:
" Brilacidin’s ability to disrupt viral integrity and block viral entry indicates it has the added potential to prevent infection, upon appropriate formulation, as a prophylactic."
https://investorshub.advfn.com/boards/read_ms...=169609082
"University of Arizona and University of California-San Francisco scientists characterized the antiviral activity of Brilacidin against multiple endemic human coronaviruses (HCoVs), including HCoV-OC43, HCoV-229E, HCoV-NL63, and SARS-CoV-2, in human cell lines...
Mechanistic studies revealed Brilacidin exerts antiviral activity by interfering with viral attachment to host cells by binding to heparan sulfate proteoglycans (HSPGs). HSPGs are important co-receptors through which different viruses gain entry into host cells, thus providing an attractive target for the development of broad-spectrum antivirals. Beyond exhibiting this blocking property, Brilacidin was also shown to target viral proteins directly, acting through a virucidal property. This dual antiviral mechanism of action suggests Brilacidin may be well-suited for prophylactic development and less likely to be subject to drug resistance.
http://www.ipharminc.com/press-release/2022/3...brilacidin
And completing the trifecta:
"Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma (P.1) and Alpha (B.1.1.7) variants of SARS-CoV-2.
Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested..."
http://www.ipharminc.com/press-release/2022/6...esearchers
Even Brilacidin's COVID-19, phase 2, that many considered a failure, provided support for Brilacidin's potential as a broad-based, anti-coronavirus prophylactic.
"If a patient started study treatment within fewer than 7 days of onset of COVID-19 symptoms, patients in the Brilacidin 5-dose group achieved sustained recovery more quickly compared to the pooled placebo group (p=0.03). For this patient population, early treatment with Brilacidin from onset of symptoms appeared to have a potential positive impact on time to sustained recovery (the study’s primary endpoint), suggesting cases that can be treated close to initial onset of disease may be an attractive population to target for Brilacidin treatment"
https://www.ipharminc.com/press-release/2022/...-use-cases
The potential for Brilacidin as a broad-spectrum, anti-coronavirus prophylactic has been demonstrated in three university's testing (in vitro) and one COVID-19 phase 2 study (in vivo).
The "Omicron" variant of COVID-19 is still a pathogen of major concern for NIAID.
"The Omicron was first detected in November 2021 and has become the most dominant strain of COVID-19...The majority of people likely infected with the omicron variant of COVID-19 were unaware, according to a study from a medical center in Los Angeles, Calif...Our study findings add to evidence that undiagnosed infections can increase transmission of the virus."
https://www.npr.org/2022/08/19/1118402942/omi...2-U9YAlny4
And just in case you were thinking there's no more "gold in them-thar COVID hills:
"According to the latest market intelligence research report by InsightAce
Analytic, the global COVID-19 Therapeutics market size was valued at US$ 10.2
Billion in 2021, and it is expected to reach US$ 25.6 Billion in 2030, record
a promising CAGR of 10.7% from 2021 to 2030."
https://www.bloomberg.com/press-releases/2022...e-analytic
Testing at 3 universities (in vitro) and B's COVID P-2 (in vivo), all indicate that B-AV's "blocking" attribute indicate it is well-suited for the role of broad-spectrum, anti-coronavirus prophylactic. B's COVID P-2 went a long way in helping researchers to see that B's role, at least insofar as COVID is concerned, is probably preventing COVID from entering the body and NOT eradicating COVID after it has built-up a strong position in the body.
The data suggest that prophylactic B-COVID will keep the virus/variant out of the body and that COVID may not be able to created a "Trojan Horse" (mutation) to get around it.
I believe NIAID will, ultimately, conduct many clinical trials, researching Brilacidin's antiviral attributes against many viral families, but, given the immediate threat still posed by COVID/Omicron and data suggesting B's ability to inhibit this virus, I think NIAID will conduct this B-COVID prophylactic trial first.
After approval and in short order, I believe B-COVID could become a billion-dollar indication practically overnight, based only on worldwide sales to governments, who will stockpile and distribute.
Message in reply to:
NIAID has a high-degree of interest in Brilacidin and I can't wait to see which direction they move in. Will it be "B" as a COVID prophylactic, broad-spectrum antiviral or possibly something involving monkeypox?
(3)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼